(Q37991749)

26 August 2017

title

Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker (English)

1 reference

26 August 2017

0 references

1 reference

Oana Vittos

1

1 reference

26 August 2017

Bogdan Toana

series ordinal

2

1 reference

26 August 2017

Alexandros Vittos

series ordinal

3

1 reference

26 August 2017

Elena Moldoveanu

series ordinal

4

1 reference

26 August 2017

publication date

9 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

17

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

289-302

1 reference

Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lp-PLA2: A new target for statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipids, risk factors and ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Anti-inflammatory therapeutics for the treatment of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

The Cytosolic Phospholipase A2 Catalytic Domain Modulates Association and Residence Time at Golgi Membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Major risk factors as antecedents of fatal and nonfatal coronary heart disease events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Structure and function of lysosomal phospholipase A2: identification of the catalytic triad and the role of cysteine residues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Prevalence of conventional risk factors in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 as a target of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

The emerging roles of PAF acetylhydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Genetic and pharmacologic evidence that calcium-independent phospholipase A2beta regulates virus-induced inducible nitric-oxide synthase expression by macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

The phospholipase A2 superfamily and its group numbering system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Localization and functional interrelationships among cytosolic Group IV, secreted Group V, and Ca2+-independent Group VI phospholipase A2s in P388D1 macrophages using GFP/RFP constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

The expanding superfamily of phospholipase A(2) enzymes: classification and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

The LDL modification hypothesis of atherogenesis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Phospholipase A2s: developing drug targets for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Calcium-independent phospholipase A(2): structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Elevated Lp-PLA 2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2012.664170

10.3109/1354750X.2012.664170

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference